linjc16/ctgov huggingface dataset:
Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain

Study Overview
=================
Brief Summary
-----------------
Fibrin sealant has been studied to reduce post-thyroidectomy drain and hospital stay as well. However, no strong evidence from well-designed clinical trials is available. Harmonic scalpel is a ultrasonic vibrating scissors which makes it easy to cut and coagulate the tissues, thus reducing op time and postoperative drain, which is important to minimize hospital stay. The investigators hypothesized that fibrin sealant combined with harmonic scalpel-assisted procedure could guarantee no-drain postoperative care in total thyroidectomy with anterior compartment neck dissection.

Official Title
-----------------
Efficacy of Fibrin Sealant to Reduce the Amount of Postoperative Drain in Patients With Harmonic Scalpel-assisted Total Thyroidectomy With Anterior Compartment Neck Dissections

Conditions
-----------------
Thyroid Carcinoma, Thyroidectomy

Intervention / Treatment
-----------------
* Drug: Usage of Fibrin sealant
* Procedure: Thyroidectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: proven thyroid carcinoma Thyroidectomy with anterior compartment neck dissection Exclusion Criteria: No use of harmonic scalpel during surgery coagulation abnormality refuse to participate

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Fibrin sealant<br>usage of fibrin sealant after surgery | Drug: Usage of Fibrin sealant<br>* Usage of 1 vial of fibrin sealant after hemostasis in total thyroidectomy with anterior compartment neck dissection<br>Procedure: Thyroidectomy<br>* surgical removal of bilateral thyroid glands<br>|
| No Intervention: Control<br>No usage of fibrin sealant | Procedure: Thyroidectomy<br>* surgical removal of bilateral thyroid glands<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative Drainage Amount | method : measurement of drainage fluids from negative suction system every 8 hr until daily total amount reduces under 20mL | serial measurement from 1day to 4day after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neck dissection
Feasibility of Mini-EEG in the Prehospital Setting

Study Overview
=================
Brief Summary
-----------------
The EEG is widely used in the diagnosis of central nervous system pathology, including epileptic seizures and epilepsy. Presently, EEG is available only during office hours in most hospitals, pending on the availability of a clinical neurophysiologist and the lack of oncall possibility outside these hours. Standard EEG devices are large and their operation require meticulous application of several leads. The department of clinical neurophysiology at Helsinki University Central Hospital has developed a mini-EEG device for use in the emergency department as well as in the prehospital setting. The aims of this pilot study is to evaluate the feasibility of the mini-EEG in the prehospital setting. Patients with a decreased level of consciousness, as evaluated by the emergency medical provider on the scene, are included. The mini--EEG device is to be used by a specially trained emergency medical supervisor. EEG is otherwise obtained in a normal fashion, but only three electrodes are used. The sample size is 30. Data are collected as a part of the clinical work in daily practice. The aim is to collect observational data on feasibility, no clinical interventions will be performed based on the EEG. No funding is needed as data is collected during daily work. The mini-EEG is a prototype EEG/EKG-adapter, designed by Helsinki Univeristy Central Hospital, and as such, does not have a trade name. It is to be connected to a monitor/defibrillator used by the EMS personel, currently the LifePak 15, manufactured by Physio-Control, Redmond, WA 98052. (www.physio-control.com)

Official Title
-----------------
Feasibility of Mini-EEG in the Prehospital Setting

Conditions
-----------------
Epilepsy, Coma

Intervention / Treatment
-----------------
* Device: Prehospital mini-EEG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Unconsciousness resulting in activation of the local EMS units Exclusion Criteria: Cardiac arrest Traumatic unconsciousness Transient unconsciousness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Prehospital mini-EEG<br>Feasibility of prehospital EEG device in unconscious patients. | Device: Prehospital mini-EEG<br>* Observational<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Signal interpretability | evaluated by a physician (ex 0=unworthy, 1=interfered, 2=good quality) | 60 min | 
| Device ease-of-use | evaluated by ems field staff (0=not fit for field use ....... 5=optimal for field use) | 60 min | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Emergency Care, Prehospital, Electroencephalography, Coma
Contrast Ultrasound in the Surveillance of Endovascular Abdominal Aortic Aneurysm Repair

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to support the suspected expectation that Contrast enhanced Ultrasound (CUS) detects all endoleaks that have been detected by Computed Tomography (CT), and also find a number of leaks missed by CT. The investigators' primary goal is to detect no difference between CT and CUS and provide evidence that CUS is a possible alternative to CT.

Official Title
-----------------
Contrast Ultrasound in the Surveillance of Endovascular Abdominal Aortic Aneurysm Repair

Conditions
-----------------
Endovascular Abdominal Aortic Aneurysm Repair

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients who underwent EVAR at The Ottawa Hospital and currently under post-EVAR surveillance at The Ottawa Hospital. Exclusion Criteria: Unable to consent for injection of contrast Unable to acquire IV access Right-to-left, bi-directional, or transient right-to-left cardiac shunts Severe pulmonary disease Previous hypersensitivity to DEFINITY® or its components Unable to be followed as a outpatient by the Vascular Diagnostic Center
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Phase 1 - Pilot phase<br>Total of 10 patients currently undergoing EVAR Surveillance. These 10 patients include 5 patients with endoleak known from a recent CT scan and 5 patients with no endoleak and shrinking aneurysm. | |
| Phase 2 - Blinded from CT Scan<br>This phase of study involves recruitment of 150 patients currently under post-EVAR surveillance. The physicians and ultrasound technologists will be blinded to the result of the CT Scan when performing and interpreting the CUS. The current schedule for EVAR Surveillance will be maintained so that an individual may receive more than one enhanced CT Scan and CUS during the 18 months of the study. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endovascular, Abdominal, Aortic, Aneurysm, Repair, Surveillance, EVAR, CT, Scan, Endoleaks, Contrast, Enhanced, Ultrasound, Definity, AAA, imaging, No Endoleaks
The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to performed a randomized controlled trial to evaluate the rate of genetic and chromosomal abnormalities in embryos obtained from GnRH-agonist long and GnRH-antagonist ovarian stimulation protocols. Patients will be prospectively randomized in two groups: the first undergoing controlled ovarian stimulation in GnRH-agonist long protocol and the second following GnRH-antagonist ovarian stimulation regimen. The end-points of the study include the number of genetically and chromosomally abnormal embryos, the pregnancy, the implantation and the healthy baby birth rate. The patients included in PGS program were selected on the base of advanced maternal age, repeated pregnancy lost and implantation failure whereas the patients who were know to carry sex-linked or monogenic disorders were considered for PGD strategy. The uterine abnormalities, endometriosis and endocrinal diseases were considered to be the exclusion factors.

Conditions
-----------------
Embryo's Genetic and Chromosomal Quality

Intervention / Treatment
-----------------
* Drug: ghrh antagonist (cetrotide/orgalutran)
* Drug: gnrh agonist (suprefact)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients carrier genetic disease advanced maternal Age repeated IVF failure recurrent pregnancy loss Exclusion Criteria: uterine abnormalities endometriosis endocrinal diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 46 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: short protocol<br>gnrh agonist versus gnrh antagonist | Drug: ghrh antagonist (cetrotide/orgalutran)<br>* cetrotide/orgalutran 0.25 mg<br>|
| Active Comparator: long protocol<br> | Drug: gnrh agonist (suprefact)<br>* suprefact 5.5 ml<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of embryos obtained from GnRH-agonist long and GnRH-antagonist ovarian stimulation protocol | difference in embryos' genetic and chromosomal quality using two different ovarian stimulation protocol | one year |
PD-1 Antibody Plus Chemotherapy for TKI Failure Driver Gene Mutation Positive Advanced NSCLC

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the efficacy and safety of PD-1 antibody plus Chemotherapy for TKI Failure EGFR/ALK/ROS1 mutation-positive advanced Non-small cell lung cancer.

Detailed Description
-----------------
Enrolled criteria EGFR mutation-positive advanced NSCLC ALK or ROS1 fusion-positive advanced NSCLC Failed with standard TKI therapy

Official Title
-----------------
PD-1 Antibody Plus Chemotherapy for TKI Failure EGFR/ALK/ROS1 Mutation Positive Advanced Non-small Cell Lung Cancer

Conditions
-----------------
Non Small Cell Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: advanced non-small cell lung cancer EGFR/ALK/ROS1 mutation positive performance status（0-1) Exclusion Criteria: other genes mutation saquamous

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PFS | Progression free survival | may 2020- may 2021 (1 year) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OS | Overall survival | may 2020- may 2021 (1 year) | 
| ORR | To measure the patients's overall response rate | may 2020- may 2021 (1 year) |
Tumor Response in Hypofractionated Radiotherapy

Study Overview
=================
Brief Summary
-----------------
This study will follow-up different immune cell populations in the blood before, during and after high dose radiation therapy which should give new information of the efficacy of Local Hypofractionated Radiotherapy and a rationale for adjuvant immunotherapy.

Detailed Description
-----------------
Patient information and collection of a signed informed consent form Clinical data collection Blood samples of 5 mL: after registration, prior to the first fraction of radiotherapy during radiotherapy sessions one month, 3 months after the last radiotherapy session Storage of the blood samples at ambient temperature Transportation of the samples to the Institute of Biology of Lille (IBL) - CNRS UMR8161 for analysis Destruction of the samples at the end of the analysis

Official Title
-----------------
Biomarkers of Tumor Response in Hypofractionated Radiotherapy

Conditions
-----------------
Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient requiring a hypofractionated irradiation; pathologically confirmed Unspecified Adult Solid Tumor Age ≥ 18 years old KPS≥70 Signed written informed consent. Exclusion Criteria: Patient treated by chemotherapy, targeted or immunotherapy within 21 days before the first sampling, Pregnant or breastfeeding woman, Patient under guardianship or tutorship.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of immune cells | The primary endpoint is the change of the percentage of immune cells before, during and after radiotherapy | prior to the first fraction of radiotherapy;14(±2) days from the begining of RT; the day (±2) of the last radiotherapy sessions ;one month, 3 months after the last radiotherapy session | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Local control | Local control of radiotherapy will be assessed based on Response Evaluation Criteria in Solid Tumors(RECIST)1.1 | 3 months | 
| Acute and Late toxicities | Acute and late toxicities will be assessed based on the common toxicity criteria for adverse events version 4.0 (CTCAEv4.0). | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Immune Marker, Immunologic Marker, Radiotherapy, Dose Hypofractionation
Macular Hemorrhage in Myopic Eyes

Study Overview
=================
Brief Summary
-----------------
Visual impairment in high myopic eyes is mainly due to the different types of myopic maculopathies, such as diffuse or patchy atrophy, lacquer cracks and choroidal neovascularization. Macular hemorrhage was one of those complications. Despite choroidal neovascularization, simple hemorrhage from rupture of Bruch's membrane and choroidal microcirculation is also the cause of hemorrhage. The prognosis of those eyes with simple hemorrhage is generally good. However, some patients had persistently poor vision after the absorption of the hemorrhage. In the literature, the visual prognosis in those patients was reported to be associated with the microstructure change under the optical coherent tomography (OCT) or the presentation of the autofluorescence. The investigators will collect the patients with high myopia and presenting with macular hemorrhage. High resolution OCT and autofluorescence imaging will be used to analyze the change of the microstructure of retina and its correlation with the visual prognosis.

Official Title
-----------------
Macular Hemorrhage in Myopic Eyes

Conditions
-----------------
Macula Lutea Hemorrhage, High Myopia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Myopia more than -6D Macular hemorrhage inside arcade Patients who are willing to visit our clinic and receive examination regularly for at least 1 year Exclusion Criteria: Patients who cannot cooperate. Macular hemorrhage unrelated to myopia

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| visual acuity | visual acuity during follow up and its correlation to other factors | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Optical coherence tomography | Change of microstructure of the retina and choroid on OCT during follow up | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Macula Lutea Hemorrhage, High Myopia, Optical Coherence Tomography
Physiological Magnetic Resonance Imaging (MRI) to Improve Carotid Endarterectomy Outcomes

Study Overview
=================
Brief Summary
-----------------
The carotid arteries are blood vessels in the neck that supply blood to the brain. Carotid stenosis disease is defined as a narrowing of these arteries due to the build up of plaque. The plaque material can also break off and move into the brain. The resulting blockage of blood supply to a portion of the brain is what causes 80% of all strokes. One treatment option is to have surgery on the carotid artery and remove the plaque. This procedure is called a carotid endarterectomy (CEA). There is evidence that proves CEA reduces the risk of stroke. The objective of this research project is to determine who is most likely to benefit from CEA surgery.

Conditions
-----------------
Carotid Stenosis, Hypoperfusion, Transient Ischemic Attack

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Greater than 30 years of age Greater than grade 9 education level Mini-mental state exam (MMSE) greater than 19 for carotid stenosis patients Exclusion Criteria: History of acute stroke History of current psychiatric disorder, such as depression or movement disorder Diagnosed Alzheimer's Disease or dementia

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Carotid endarterectomy patients<br> | |
| Lumbar stenosis laminectomy patients<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Functional MRI (fMRI) results will be used to calculate the activation-related hemodynamic response function (HRF) in patients undergoing carotid endarterectomy, which will be significantly reduced post-operative at 3 months follow-up. |  | Pre-operative, 3 months post-operative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dynamic intracranial angiography will be correlated with arterial arrival time (AAT) hemodynamic metric calculated from arterial spin labeling (ASL) perfusion MRI. |  | Pre-operatively, 3 months post-operatively |
WGS-guided Tracking and Infection Control Measures of CRKP

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to investigate the effect of the infection control measures based on the active screening of carbapenem-resistant Klebsiella pneumoniae and whole-genome based tracking and surveillance though the hospital.

Official Title
-----------------
WGS-guided Tracking and Infection Control Measures of Carbapenem-resistant Klebsiella Pneumoniae

Conditions
-----------------
Klebsiella Pneumoniae Infection

Intervention / Treatment
-----------------
* Other: screen of CRKP and infection control measure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patient was admitted to the ICU of neurosurgery in the west hospital of huashan hospital affiliated to fudan university from September 2019 to September 2021, or transferred from the ICU of another hospital The patient is more than 18 years old and less than 80 years old, regardless of gender. Informed consent of the patient; Exclusion Criteria: Patients participating in other clinical trials at the same time Pregnant 4. People who will affect the outcome of the study: whose specimens could not be received or not enough for testing

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: WGS-based screen and control group<br>For intervention group, we screen admitted patients for carbapenem-resistant Klebsiella pneumoniae and carry out 'Bundle' infection and control measures. When outbreak or tranmission of CRKP was observed, we take whole-genome sequencing to track origin and transmission route to decease CRKP rate. | Other: screen of CRKP and infection control measure<br>* For intervention group, we screen admitted patients for carbapenem-resistant Klebsiella pneumoniae and carry out 'Bundle' infection and control measures. When outbreak or tranmission of CRKP was observed, we take whole-genome sequencing to track origin and transmission route to decease CRKP rate.<br>|
| No Intervention: Non-intervention<br>Non-intervention | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the influence of WGS-based screen and control measures on the CRKP occurrence rate |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analysis of transmission pattern and route pre and post WGS-based tracking |  | 2 years |